VANGUARD GROUP INC - NEOLEUKIN THERAPEUTICS INC ownership

NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 41 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
VANGUARD GROUP INC ownership history of NEOLEUKIN THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$838,974
+17.9%
1,010,812
-0.5%
0.00%
Q1 2023$711,407
+37.5%
1,016,2960.0%0.00%
Q4 2022$517,295
-21.3%
1,016,296
-0.9%
0.00%
Q3 2022$657,000
-43.2%
1,025,886
-8.7%
0.00%
Q2 2022$1,157,000
-51.9%
1,123,205
-12.3%
0.00%
Q1 2022$2,407,000
-68.8%
1,280,501
-20.0%
0.00%
Q4 2021$7,712,000
-33.8%
1,600,003
-0.7%
0.00%
Q3 2021$11,644,000
-20.8%
1,610,572
+1.1%
0.00%
Q2 2021$14,709,000
-21.3%
1,593,582
+5.0%
0.00%
-100.0%
Q1 2021$18,692,000
+14.9%
1,518,403
+31.6%
0.00%
Q4 2020$16,265,000
+24.5%
1,153,490
+5.9%
0.00%
Q3 2020$13,069,000
-20.8%
1,089,020
+9.5%
0.00%
-100.0%
Q2 2020$16,506,000
+175.0%
994,339
+88.5%
0.00%
Q1 2020$6,002,000
-6.6%
527,451
+1.1%
0.00%
Q4 2019$6,429,000
+819.7%
521,850
+112.6%
0.00%
Q3 2019$699,000245,4080.00%
Other shareholders
NEOLEUKIN THERAPEUTICS INC shareholders Q1 2023
NameSharesValueWeighting ↓
Opaleye Management Inc. 1,386,300$19,547,0002.55%
EcoR1 Capital, LLC 3,122,704$44,030,0002.37%
Redmile Group, LLC 4,131,869$58,259,0000.70%
Boxer Capital, LLC 1,501,058$21,165,0000.68%
HighVista Strategies LLC 69,727$983,0000.63%
Baker Brothers Advisors 3,821,740$53,887,0000.20%
Highland Private Wealth Management 93,998$1,326,0000.12%
Sio Capital Management, LLC 38,312$540,0000.11%
Point72 Asset Management, L.P. 1,195,725$16,860,0000.08%
Granahan Investment Management 246,299$3,473,0000.08%
View complete list of NEOLEUKIN THERAPEUTICS INC shareholders